bezafibrate has been researched along with fibrinogen in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.81) | 18.7374 |
| 1990's | 20 (54.05) | 18.2507 |
| 2000's | 10 (27.03) | 29.6817 |
| 2010's | 3 (8.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franceschini, G; Gianfranceschi, G; Maderna, P; Mannucci, L; Mussoni, L; Pazzucconi, F; Sirtori, CR; Tremoli, E; Werba, P | 1 |
| Kleinert, G; Lechner, H; Schied, H; Walzl, B; Walzl, M | 1 |
| Bhatnagar, D; Durrington, PN; Winocour, PH | 1 |
| Barradas, MA; Dandona, P; Mathur, S; Mikhailidis, DP | 1 |
| Green, KG; Heady, A; Oliver, MF | 1 |
| Caimi, G; Catania, A; Francavilla, G; Romano, A; Santonocito, G; Sarno, A | 1 |
| Bulgarelli, A; Cassader, M; Niort, G; Pagano, G | 1 |
| Berent, H; Kuczyńska, K; Młyński, J | 1 |
| Barasch, E; Behar, S; Benderly, M; Caspi, A; Goldbourt, U; Graff, E; Pelled, B; Reicher-Reiss, H; Reisin, L; Roguin, N | 1 |
| Barbir, M; Galloway, D; Hunt, BJ; Ilsley, C; Mitchell, A; Taylor, A; Yacoub, M | 1 |
| Bertha, G; Freidl, W; Kleinert, G; Lechner, H; Schied, G; Walzl, B; Walzl, M | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Lechner, H; Schied, G; Walzl, B; Walzl, M | 1 |
| de Faire, U; Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B | 1 |
| Barradell, LB; Goa, KL; Plosker, GL | 1 |
| Fujishlma, M; Iwase, M; Takano, K; Waklsaka, M; Yamamoto, M; Yoshinari, M | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Castro, P; Concha, M; Jimenéz-Perepérez, JA; López-Miranda, J; Montilla, P; Pérez-Jiménez, F; Vallés, F; Velasco, F; Zambrana, JL | 1 |
| Binsack, R; Dörge, L; Stegmeier, K; Völkl, A | 1 |
| Dhanjil, S; Diamond, JR; Elkeles, RS; Feher, MD; Mahmood, S; Mather, H; Nicolaides, AN; Poulter, C; Richmond, W; Sharp, P | 1 |
| Arrol, S; Bhatnagar, D; Durrington, PN; Julier, K; Mackness, MI; Morgan, J; Prais, H; Wood, GN | 1 |
| Behar, S; Brunner, D; Goldbourt, U; Reicher-Reiss, H | 1 |
| Coufal, Z; Urbánek, R | 1 |
| Behar, S | 1 |
| Boschetti, C; Cofrancesco, E; Cortellaro, F; Cortellaro, M; Mancini, M; Mariani, M; Paoletti, R | 1 |
| de Man, FH; Gevers Leuven, JA; Nieuwland, R; Romijn, F; Smelt, AH; Sturk, A; van der Laarse, A | 1 |
| Hirano, T; Kazumi, T; Yoshino, G | 1 |
| Behar, S; Benderly, M; Boyko, V; Brunner, D; Goldbourt, U; Graff, E; Mandelzweig, L; Reicher-Reiss, H; Shotan, A; Tanne, D | 1 |
| Jonkers, IJ; Mohrschladt, MF; Smelt, AH; van der Laarse, A; Westendorp, RG | 1 |
| Flavell, DM; Hawe, E; Humphries, SE; Jamshidi, Y; MacCallum, PK; Meade, TW | 1 |
| Adler, Y; Behar, S; Boyko, V; Goldbourt, U; Haim, M; Matetzky, S; Mekori, YA; Reshef, T; Tanne, D | 1 |
| Brennan, SO; George, PM; Maghzal, GJ | 1 |
| Adler, Y; Behar, S; Benderly, M; Fisman, EZ; Goldbourt, U; Haim, M; Matas, Z; Tanne, D; Tenenbaum, A; Zimmlichman, R | 1 |
| Krysiak, R; Okopien, B | 1 |
| Behar, S; Benderly, M; Eisen, A; Goldbourt, U; Haim, M | 1 |
| Brenner, R; Gerber, Y; Goldenberg, I; Hasin, T; Iakobishvili, Z; Klempfner, R; Kornowski, R; Shlomo, N | 1 |
2 review(s) available for bezafibrate and fibrinogen
| Article | Year |
|---|---|
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Topics: Angina Pectoris; Apolipoproteins; Apolipoproteins A; Bezafibrate; Diabetes Complications; Drug Tolerance; Fibrinogen; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Myocardial Infarction | 1996 |
[BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
Topics: Bezafibrate; Cholesterol, HDL; Coronary Artery Disease; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
24 trial(s) available for bezafibrate and fibrinogen
| Article | Year |
|---|---|
Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
Topics: Adult; Aged; Bezafibrate; Female; Fibrinogen; Fibrinolysis; Humans; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Tissue Plasminogen Activator | 1992 |
[H.E.L.P. (heparin-induced extracorporeal LDL precipitation) and bezafibrate--a new therapeutic combination in cerebrovascular diseases].
Topics: Aged; Bezafibrate; Blood Viscosity; Chemical Precipitation; Combined Modality Therapy; Dementia, Multi-Infarct; Double-Blind Method; Fibrinogen; Hemoperfusion; Heparin; Humans; Lipoproteins, LDL; Neuropsychological Tests; Plasmapheresis; Triglycerides | 1992 |
Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
Topics: Adolescent; Adult; Aged; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 1; Female; Fibrinogen; Humans; Lipoproteins; Male; Middle Aged | 1990 |
The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
Topics: Adenosine Diphosphate; Bezafibrate; Blood Glucose; Blood Platelets; Cholesterol; Collagen; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fibrinogen; Homeostasis; Humans; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Triglycerides | 1990 |
Blood rheology changes during bezafibrate treatment.
Topics: Aged; Arteriosclerosis; Bezafibrate; Blood Viscosity; Clinical Trials as Topic; Double-Blind Method; Fibrinogen; Hematocrit; Humans; Middle Aged; Random Allocation | 1988 |
Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients.
Topics: Adult; Aged; Arteriosclerosis; Bezafibrate; Blood Coagulation Disorders; Blood Platelets; Fibrinogen; Fibrinopeptide A; Humans; Middle Aged; Platelet Aggregation; Random Allocation; Rheology | 1988 |
Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study.
Topics: Age Factors; Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Fibrinogen; Humans; Hypertension; Israel; Male; Middle Aged; Motor Activity; Multivariate Analysis; Myocardial Infarction; Risk Factors; Sex Factors; Smoking; Triglycerides | 1995 |
A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
Topics: Analysis of Variance; Bezafibrate; Colestipol; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor VII; Factor VIII; Female; Fibrinogen; Fibrinolysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1994 |
[Hemorrheology and quality of life in fibrinogen- and lipid-lowering therapy].
Topics: Aged; Bezafibrate; Blood Viscosity; Cholesterol, LDL; Dementia, Multi-Infarct; Double-Blind Method; Female; Fibrinogen; Hemofiltration; Heparin; Humans; Lipids; Male; Mental Status Schedule; Quality of Life | 1993 |
[Association between fibrinogen and blood sedimentation rate in combined extracorporal and fibrinogen reducing drug therapy].
Topics: Aged; Bezafibrate; Blood Component Removal; Blood Sedimentation; Cerebral Infarction; Combined Modality Therapy; Dementia, Multi-Infarct; Double-Blind Method; Female; Fibrinogen; Humans; Lipoproteins, LDL; Male; Middle Aged | 1993 |
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Feasibility Studies; Fibrinogen; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Risk Factors; Time Factors; Triglycerides | 1996 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
Topics: Bezafibrate; Cross-Over Studies; Female; Fibrinogen; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Lovastatin; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies | 1997 |
Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Topics: Adult; Aged; Bezafibrate; Carotid Arteries; Cholesterol; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Electrocardiography; Exercise Test; Female; Femoral Artery; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Placebos; Time Factors; Triglycerides; Ultrasonography | 1998 |
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Topics: Adult; Aged; Aryldialkylphosphatase; Bezafibrate; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Double-Blind Method; Esterases; Female; Fibrinogen; Gemfibrozil; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Plasminogen Activators | 1998 |
Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Treatment Outcome; Triglycerides | 1998 |
Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention.
Topics: Aged; Bezafibrate; Coronary Disease; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Treatment Outcome | 1999 |
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Trea
Topics: Adult; Aged; Bezafibrate; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Tissue Plasminogen Activator; Treatment Outcome | 2000 |
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
Topics: Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol, HDL; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Survival Analysis; Treatment Outcome; Triglycerides | 2000 |
Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy.
Topics: Antigens, CD; Bezafibrate; Blood Platelets; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Fibrinogen; Flow Cytometry; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Membrane Glycoproteins; Tetraspanin 30; Triglycerides | 2000 |
A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study.
Topics: Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Regression Analysis; Risk; Severity of Illness Index; Stroke; Triglycerides | 2001 |
Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
Topics: Bezafibrate; Blood Glucose; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Female; Fibrinogen; Humans; Hypertriglyceridemia; Hypolipidemic Agents; In Vitro Techniques; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Interleukin-6; Lipids; Male; Middle Aged; Tumor Necrosis Factor-alpha | 2002 |
Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein C-III; Apolipoproteins C; Arterial Occlusive Diseases; Base Sequence; Bezafibrate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Hypolipidemic Agents; Male; Middle Aged; Molecular Sequence Data; Peripheral Vascular Diseases; Polymerase Chain Reaction; Polymorphism, Genetic; Probability; Reference Values; Sensitivity and Specificity; Treatment Outcome | 2002 |
Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease.
Topics: Age Factors; Aged; Bezafibrate; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Female; Fibrinogen; Follow-Up Studies; Heart Failure; Humans; Hypolipidemic Agents; Incidence; Inflammation; Israel; Leukocyte Count; Male; Middle Aged; Risk Factors; Time Factors | 2014 |
11 other study(ies) available for bezafibrate and fibrinogen
| Article | Year |
|---|---|
Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate.
Topics: Bezafibrate; Clofibrate; Coronary Disease; Fibrinogen; Humans; Hypertension; Male; Smoking; World Health Organization | 1989 |
[The effect of bezafibrate on the level of serum lipids, fatty acid lecithin-cholesterol transferase activity and certain parameters of the fibrinolytic system in patients with type IIb and type IV hyperlipoproteinemia].
Topics: Adult; Bezafibrate; Female; Fibrinogen; Fibrinolysis; Humans; Hyperlipoproteinemias; Lipids; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase | 1985 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Bezafibrate; Blood Coagulation; Body Mass Index; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prothrombin Time | 1997 |
Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cells.
Topics: Acute-Phase Reaction; Animals; Bezafibrate; Biological Transport; Carcinoma, Hepatocellular; Cattle; Dose-Response Relationship, Drug; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fetal Blood; Fibrinogen; Humans; Intracellular Fluid; Lectins; Liver Neoplasms; Neoplasm Proteins; Precipitin Tests; RNA, Neoplasm; Tumor Cells, Cultured | 1998 |
[Bezafibrate in the treatment of familial combined hyperlipidemia and its effect on certain parameters of lipid metabolism, particularly fibrinogen].
Topics: Adult; Bezafibrate; Female; Fibrinogen; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged | 1998 |
Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.
Topics: Bezafibrate; Biomarkers; Brain Ischemia; Case-Control Studies; Chronic Disease; Cohort Studies; Comorbidity; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Israel; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Risk Factors; Stroke | 2002 |
The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy.
Topics: Bezafibrate; Case-Control Studies; Female; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; N-Acetylneuraminic Acid; Pregnancy; Protein Subunits; Spectrometry, Mass, Electrospray Ionization; Thrombin Time | 2005 |
C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease.
Topics: Aged; Angina Pectoris; Bezafibrate; Brain Ischemia; C-Reactive Protein; Cerebral Infarction; Female; Fibrinogen; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Israel; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Risk Assessment | 2006 |
Hemostatic effects of omega-3 fatty acids in isolated hypertriglyceridemic patients treated with bezafibrate.
Topics: Adult; Aged; Antigens; Bezafibrate; Drug Therapy, Combination; Factor VII; Fatty Acids, Omega-3; Female; Fibrinogen; Hemostasis; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Partial Thromboplastin Time; Plasminogen Activator Inhibitor 1; Prothrombin Time; von Willebrand Factor | 2012 |
Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinogen; Humans; Hypolipidemic Agents; Israel; Lipids; Male; Middle Aged; Neoplasms; Registries; Risk Reduction Behavior; Triglycerides | 2019 |